DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Tezacitabine (FMdC)

First Posted Date: 2003-06-02

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00061620

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Mitoxantrone (Novantrone)
Drug: Bortezomib (PS-341)

First Posted Date: 2003-04-30

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00059631

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-04-30

Last Posted Date: 2012-02-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00059605

Locations: 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: PS-341 (Bortezomib)
Drug: Carboplatin

First Posted Date: 2003-04-30

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00059618

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cytarabine
Drug: cyclophosphamide
Drug: methotrexate
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate

First Posted Date: 2003-04-25

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00003311

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Interaction Between Patient and Healthcare Provider: Response to Acupuncture in Knee Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Procedure: Acupuncture
Procedure: Placebo acupuncture
Other: Usual Care

First Posted Date: 2003-04-24

Last Posted Date: 2013-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 639

Registration Number: NCT00059345

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim (G-CSF)
Biological: Bleomycin Sulfate (BLM)
Biological: Recombinant Interferon Alfa
Drug: Carmustine
Drug: Cytarabine (ARA-C)
Drug: Cisplatin (CDDP)
Drug: Etoposide (VP-16)
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Idarubicin
Drug: Melphalan
Drug: Leucovorin Calcium
Drug: mitoxantrone hydrochloride (DHAD)
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Methylprednisolone
Drug: Vincristine Sulfate
Radiation: Radiation Therapy

First Posted Date: 2003-04-16

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00002835

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Phase 2

Completed

Conditions: Skin Cancer

Interventions: Drug: Iressa

First Posted Date: 2003-02-07

Last Posted Date: 2015-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00054691

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Phase 3

Completed

Conditions: Leukemia, Myeloid, Chronic

Interventions: Drug: Gleevec
Drug: Peg-alpha interferon (Peg-Intron)
Drug: Sargramostim (GM-CSF)

First Posted Date: 2003-02-07

Last Posted Date: 2016-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 94

Registration Number: NCT00050531

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Doxorubicin hydrochloride
Drug: Docetaxel
Radiation: Strontium chloride Sr 89
Drug: Estramustine phosphate sodium
Drug: Prednisone
Drug: Ketoconazole
Drug: Dexamethasone
Drug: Vinblastine

First Posted Date: 2003-01-27

Last Posted Date: 2016-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 265

Registration Number: NCT00024167

Locations: 🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸
University of Mississippi Cancer Clinic, Jackson, Mississippi, United States

and more 36 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy